Table 3.
Outcome Measures of Effectiveness Among Randomized Patients
| |
Week 12a |
Week 24 |
|
|
|
|
||
|---|---|---|---|---|---|---|---|---|
| Measure | n | Mean (SD) | n | Mean (SD) | F | df | p | Partial eta-square |
| BPRS totalb | ||||||||
| Clozapine | 13 | 31.1 (8.4) | 13 | 31.7 (12.1) | 1.36 | 1, 30 | .25 | .04 |
| Olanzapine | 19 | 34.7 (14.3) | 19 | 30.3 (9.8) | ||||
| BPRS Psychosis Clusterb | ||||||||
| Clozapine | 14 | 6.1 (2.1) | 14 | 6.6 (3.2) | .83 | 1, 30 | .37 | .03 |
| Olanzapine | 18 | 7.9 (4.7) | 18 | 7.3 (3.7) | ||||
| SANS total scorec | ||||||||
| Clozapine | 14 | 6.1 (3.6) | 14 | 6.6 (4.9) | 3.7 | 1, 31 | .06 | .11 |
| Olanzapine | 19 | 7.4 (3.9) | 19 | 5.4 (3.8) | ||||
| CGI-Improvementd | ||||||||
| Clozapine | 14 | 2.0 (.73) | 14 | 2.4 (1.3) | 8.34 | 1, 31 | .007 | .21 |
| Olanzapine | 19 | 2.9 (1.3) | 19 | 1.9 (.78) | ||||
| CGASe | ||||||||
| Clozapine | 14 | 49.5 (14.1) | 14 | 46.9 (16.8) | 1.98 | 1, 30 | .17 | .06 |
| Olanzapine | 18 | 48.5 (19.8) | 18 | 55.6 (17.5) | ||||
All data are presented as mean (standard deviation). Using an intention-to-treat analysis, data are presented for subjects based on their initial randomization assignment to the clozapine or olanzapine group in the double-blind study (Kumra et al. 2008), regardless of which drug they received during the current open-label 12-week extension study.
a
Or trial end point.
b
Brief Psychiatric Ratings Scale.
c
Scale for the Assessment of Negative Symptoms. Total Score = sum of global scores (affective flattening, alogia, avolition, asociality-an-hedonia).
d
Clinical Global Impressions—Improvement Scale.
e
Children's Global Assessment Scale.